Exclusive Enteral Nutrition Initiates Individual Protective Microbiome Changes to
Induce Remission in Pediatric Crohn's Disease

Häcker, Deborah[1,2]; Siebert, Kolja[3]; Smith, Byron J[4+]; Köhler, Nikolai[5]; Mahapatra, Aritra[6];
Heimes, Helena[1]; Metwaly, Amira[1]; Hölz, Hannes[3]; Manz, Quirin[8]; De Zen, Federica[3];
Heetmeyer, Jeannine[3]; Socas, Katharina[3]; Le Thi, Giang[3]; Meng, Chen[7]; Kleigrewe, Karin[7];
Pauling, Josch K[5]; Neuhaus, Klaus[6]; List, Markus[8]; Pollard, Katherine S[4,9,10]; Schwerd,
Tobias[3&+]; Haller, Dirk[1,2,11&+]

[&]Authors contributed equally, [+]Corresponding author

9
[1] Chair of Nutrition and Immunology, TUM School of Life Sciences, Technische Universität
München, Freising, Germany
[2] TUMCREATE, 1 CREATE Way, #10-02 CREATE Tower, Singapore 138602
[3] Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU
Munich, Germany.
[4] Gladstone Institutes, San Francisco, CA, USA
[5] LipiTUM, Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical
University of Munich, Freising, Germany
[6] Core Facility Microbiome, ZIEL Institute for Food & Health, Technische Universität München,
Freising, Germany
[7] Bavarian Center for Biomolecular Mass Spectrometry (BayBioMS), TUM School of Life
Sciences, Technische Universität München, Freising, Germany
[8] Data Science in Systems Biology, School of Life Sciences, Technische Universität München,
Freising, Germany
[9] University of California, San Francisco, CA, USA
[10] Chan Zuckerberg Biohub
[11] ZIEL Institute for Food & Health, Technische Universität München, Freising, Germany

Abstract

Exclusive enteral nutrition (EEN) is the first-line therapy for pediatric Crohn's disease (CD), but
protective mechanisms remain unknown. We established a prospective pediatric cohort to
characterize the function of fecal microbiota and metabolite changes of treatment-naïve CD
patients in response to EEN. Integrated multi-omics analysis identified network clusters from
individually variable microbiome profiles, with *Lachnospiraceae* and medium chain fatty acids
as protective features. Metagenomic analysis identified high strain-level dynamics in response
to EEN cessation, and hundreds of bacterial gene functions with significant changes in
abundance. Functional changes of diet-exposed fecal microbiota were further validated in a
combined approach using gut chemostat cultures and microbiota transfer into germ-free *Il10*-
deficient mice. EEN-like and fiber-repleted dietary model conditions, respectively, induced
individual strain signatures to prevent or cause IBD-like inflammation in gnotobiotic mice.
Hence, we provide evidence that EEN therapy operates through explicit functional changes of
temporally and individually variable microbiome profiles.

Keywords: Crohn's disease, pediatric, EEN, inflammatory bowel diseases, IBD, diet, fiber,

fermentation, gut chemostat, FMT, data integration, microbiome, metabolome, microbial

strains

Introduction

Crohn's disease (CD), one of the main entities of inflammatory bowel diseases (IBD), is a chronic and relapsing inflammatory condition of the gastrointestinal tract[1]. Epidemiological studies have demonstrated a significant increase in the incidence of CD in Westernized countries, particularly among the pediatric age group[2,3]. The pathogenesis of IBD involves host genetics and environmental influences, among which diet and the intestinal microbiome are key etiologic factors[4,5].

Exclusive enteral nutrition (EEN) is the first-line treatment for pediatric CD[6,7] and also shows efficacy in adult patients[8]. EEN refers to polymeric liquid formulas, which are mostly devoid of fibers[9]. Re-introducing regular diet after 6-8 weeks of EEN often results in recurrence of inflammation and disease activity[10]. EEN has been shown to drive changes in gut microbiota composition[11], but the high relapse rate after cessation of EEN suggests the presence of a CD-conditioned microbiome, which is able to re-establish after dietary intervention[12]. CD is associated with reduced bacterial diversity, compositional and functional changes, and the disruption of metabolic circuits between microbiome and host[13–15], however functional evidence for EEN-mediated changes in the microbiome as an underlying cause of therapeutic efficacy is still lacking.

Here, we identify EEN-protective signatures using integrated microbiota and metabolite analysis of treatment-naïve pediatric CD patients. Further, we functionally validate EEN-mediated protective changes in the microbiome using fecal microbiota transfer (FMT) from patients into *ex vivo* gut chemostat and germ-free (GF) *Il10*[-/-] mouse models. These systems allowed us to investigate the impact of diet on patient-derived fecal microbiota independent of the host, demonstrating that EEN directly shapes individual microbiomes to mediate protective functions in treatment-naïve CD patients.

Results

Microbiota and metabolite profiling identify individual responses to EEN therapy in pediatric CD patients

We established a pediatric IBD cohort and longitudinally followed 78 IBD patients (36 female, age at study inclusion 12.2 ± 3.9 years, 46 newly diagnosed) (**Fig. 1a, Extended Data Table 1**). Fecal samples from this cohort showed no clustering based on disease phenotype (CD, UC/IBDU) or EEN-exposure (**Fig. 1b, c,** 16S rRNA gene amplicon sequencing: 804 fecal samples [exposure antibiotics/probiotic n = 18/10] from 78 patients; untargeted metabolomic profiling: 467 fecal samples from 59 patients).

From the thirty-seven CD patients receiving EEN, we then focused explicitly on the 20 newly
diagnosed and treatment naïve CD-EEN patients (**Fig. 1a, Extended Data Table 1**). At the
end of EEN therapy, disease activity and inflammatory markers improved significantly, resulting
in clinical response and induction of remission in 20/20 and 18/20 patients, respectively (**Fig.
1d**). During follow-up, patients received methotrexate (6/20), anti-TNF (13/20), or combination
therapies (9/13) as maintenance treatment. Relapse after EEN was observed in 8/20 patients
over one-year follow-up (**Fig. 1d**). Two patients switched from Modulen IBD® to Neocate
Junior® during EEN due to suspected cow's milk protein allergy.

Analysis of samples before (PreEEN), during (EEN), and after EEN therapy (PostEEN)
(microbiota profiling: 291 samples, metabolomic analysis: 145 samples) revealed patient-
specific responses (**Fig. 1e, f and j**). Bacterial richness based on zOTUs (zero-radius
operational taxonomic units) changed individually during formula feeding (**Fig. 1e, Extended
Data Fig. 1a**), but was lower during active CD compared to remission (**Extended Data Fig.
1b, c**). Reminiscent of the total cohort, dendrograms of microbiota and metabolome analyses
showed no EEN-specific clustering (**Fig. 1f, j**). Despite considerable overlap in multi-
dimensional scaling (MDS) plots, microbial profiles were significantly different for: patients with
active *vs*. inactive disease (**Fig. 1g**, n = 281, p = 0.001), during EEN intervention *vs*. PostEEN
(**Fig. 1h,** n = 174**,** p-value = 0.001), and during early *vs*. late EEN exposure (**Fig. 1i**, n = 70, p-
value = 0.017). PCA plots of metabolic profiles (**Fig 1k-m**) showed separation according to
disease activity **(Fig 1k)**, but weaker partitioning by diet (**Fig 1l**) and no separation by EEN
duration (**Fig 1m**).

Integration of microbiota and metabolome data identifies key features of EEN exposure

Network analysis incorporating zOTU taxonomic profiles and untargeted metabolomics from
60 samples identified interlinked features, clustering in five distinct network communities (**Fig.
2a**). The communities with the highest performance in predicting EEN *vs*. PostEEN were
identified (**Fig. 2b-d** based on Receiver Operating Characteristic (ROC)-Area under the Curve
(AUC)) and the respective feature importance of the integrated data are displayed (**Fig. 2e-g**,
Community 4 and 5 are shown in **Extended Data Fig. 2a, b**). In summary, we identified 16
zOTUs relevant for the integrated EEN signature and 9 zOTUs for the integrated PostEEN
signature, including several zOTUs from the genera *Enterocloster* and *Clostridium* (formerly
Lachnoclostridium; Lachnospiraceae) (**Fig. 2h, Extended Data Fig. 2c**). Most metabolites
were predictive for PostEEN (n = 68), while 10 metabolites were linked to the protective effect
of EEN (**Fig. 2e-g**, **Extended Data Fig. 2a, b** for Community 4 and 5). Of these, palmitoleic
acid, lauric acid, decanoic acid and caprylic acid were identified as metabolite features present
in Modulen IBD® (**Extended Data Fig. 2d**).

Microbial strains and functions change dramatically at EEN cessation

Next, we collected shotgun metagenomes for 96 CD-EEN patient samples (n = 19 patients) to

investigate the transition off of EEN. We detected 577 bacterial protein families with substantial

changes in abundance (45 increased and 532 decreased) at the transition off of EEN (**Fig. 3a**).

Families increased during EEN included COG3845 (mean log2 PostEEN/EEN of -0.68) and

COG4603 (-0.65), components of the ABC-type guanosine uptake system. Increases in

COG4813 (+1.67), annotated as trehalose utilization protein, and COG3867 (+0.98),

arabinogalactan endo-1,4-beta-galactosidase, indicate that microbes encoding these proteins

respond to host diet and may play a role in metabolite transformations. These findings are

consistent with changes in hexoses, disaccharides, and sugar acids found in the metabolite

analysis (**Fig. 2e-g**).

Computing the dissimilarity between pairs of samples from the same patient showed that

taxonomic turnover increased with time between samples (**Fig. 3b, c**). We observed

significantly more turnover in zOTU composition between pairs of samples across the

transition off of EEN ($p < 10^{-3}$ for both by permutation test) than during the EEN and PostEEN

time period (**Fig. 3b**). We next applied StrainFacts[16] to resolve taxonomic differences below

the level of species. Overall, we observed high strain-level diversity within and between CD-

EEN patients. For most of the 369 species, strains were largely specific to a single patient and

appeared in multiple samples from their host, while some samples contained multiple distinct

strains of a given species (**Supplementary Fig. 2**). We detected elevated strain turnover

during the transition off of EEN relative to the PostEEN period ($p < 10^{-3}$, **Fig. 3c**).

To further integrate 16S and metagenomic results, we identified pairs of zOTUs and

metagenomic species with relative abundance profiles that were highly correlated across

samples (e.g. **Fig. 3d**). This approach matched 26 zOTUs to one or more metagenomic

species (**Fig. 3e; Extended Data Table 2**), accounting for a median of 40% of relative

abundance per sample. Thus, metagenomics augmented amplicon sequencing, increased the

taxonomic resolution of our microbiome profiling, and revealed longitudinal dynamics in

microbial communities that was greatest at the transition off of EEN.

Next, we identified species with extensive strain turnover, large changes in relative abundance

at the end of EEN, high mean relative abundance, and high prevalence (**Fig. 3f**, **Extended**

Data Table 3, top 20). Using this composite score, we flagged 28 species as highly dynamic

and many of the top scoring species matched zOTUs (**Fig. 2**). Here we highlight the strain

dynamics of two closely related species, *Enterocloster bolteae* (formerly *Lachnoclostridium*

bolteae) and *E. clostridioformis* (formerly *C. clostridioforme*). Both of these metagenomic

species matched zOTU5 (**Fig. 3d, f**) and showed clear shifts in strain composition at or near

the transition off of EEN (**Fig. 3g, h**). In some patients, EEN and PostEEN samples contained

similar strains of each species, but the dominant strain changed; in others, a new strain

appeared PostEEN that was absent or undetectable during EEN. In contrast to *E.*

clostridioformis, the relative abundance of *E. bolteae* was significantly affected by EEN

cessation. Furthermore, while individual strains of this species did seem to respond to EEN

cessation, it had lower strain diversity and turnover overall (**Fig. 3h**). This distinction among

strains and between closely related species reinforces the importance of strain-level

characterization in individuals.

Altogether, metagenomic analyses demonstrate that gut microbial communities are dynamic

at and below the species level and highly influenced by EEN, motivating us to explore their

relationship to the clinical efficacy of EEN.

EEN-like diet triggers protective changes in fecal microbiota

To further evaluate the functional impact of EEN on patient-derived fecal microbiota, we used

continuous culture systems in a gut chemostat model and fecal microbiota transfer (FMT) into

GF WT and *Il10*$^{-/-}$ mice. *Il10*$^{-/-}$ mice are a microbiota-dependent IBD mouse model responsive

to human fecal microbiota, as previously shown for adult CD patients[17] (**Fig. 4a**). We selected

fecal samples from model patients (MP) at different disease states and response to therapy

(**Fig. 4b, c, i**).

Microbiota transfer of the PreEEN sample of MP1 (MP1-FMT 1, **Fig. 4b,** red arrow) induced

colonic tissue inflammation in all gnotobiotic *Il10*$^{-/-}$ mice (histopathology score of 5.3 ± 1.0) but

not in WT control mice (**Fig. 4d** p = 0.002, histopathology score of 1.3 ± 0.5; **Supplementary**

Fig. 3a H&E), mirroring the active disease state of this patient. Following transfer of MP1 fecal

material into the gut chemostat model (MP1-FMT 2, **Fig 4a**), dietary exposure was mimicked

using combinations of fiber-free EEN-like and fiber-repleted (FR) medium, respectively

(**Extended Data Fig. 3a, b**). We then transferred microbiota (MP1-FMT 3) from the chemostat

model exposed to EEN-like medium and thereby reversed the inflammatory phenotype of MP1

in *Il10*$^{-/-}$ mice (**Fig. 4d**, histopathology score of *Il10*$^{-/-}$ mice = 2.5 ± 0.8; WT mice = 1.6 ± 0.5;

Fig. 4f, H&E, **Supplementary Fig. 3a**). Conversely, under fiber-repleted medium conditions

MP1-FMT 4 induced IBD-like tissue pathology in four out of six *Il10*$^{-/-}$ mice (**Fig. 4d**

histopathology score = 3.7 ± 1.0; **Fig. 4f** H&E, **Supplementary Fig. 3a**), compared to disease-

free WT mice (**Fig. 4d** histopathology score = 1.4 ± 0.5, p = 0.0087; **Fig. 4f** H&E,

Supplementary Fig. 3a). *Tnf* gene expression confirmed active tissue inflammation with

significantly elevated expression levels in *Il10*$^{-/-}$ compared to WT mice (**Fig. 4f** p = 0.0022 dist.

colon; **Supplementary Fig. 3d** p = 0.0152 prox. colon). Thus, *ex vivo* EEN-like intervention

recapitulated therapeutic functional changes to the microbiota.

Transfer of the fecal microbiota from MP2 failed to induce inflammation in $Il10^{-/-}$ mice (MP2-

FMT 1, **Fig 4e** H&E, **Supplementary Fig. 3b**), resembling the inactive disease state of the

patient. Since the stool sample of MP2 was retrieved under EEN therapy, we started the gut

chemostat on EEN-like medium (MP2-FMT 2; **Extended Data Fig. 3c**). In contrast to MP2-

FMT 3 (**Fig. 4e** histopathology score in in $Il10^{-/-}$ = 2.0 ± 0.6; WT = 1.0 ± 0.6; **Fig. 4g** H&E,

Supplementary Fig. 3b), transfer of FR-conditioned microbiota (MP2-FMT 4) triggered IBD-

like colitis, including histopathologic changes and elevated *Tnf* tissue expression (**Fig. 4e**,

histopathology score in $Il10^{-/-}$ = 4.8 ± 1.9 *vs*. WT = 1.5 ± 0.5, p = 0.0152; **Fig. 4g** H&E, *Tnf* gene

expression p = 0.0152 dist. colon; **Supplementary Fig. 3d** p = 0.0022 prox. colon). Thus, both

transfer experiments (MP2-FMT 1 and MP2-FMT 3) demonstrate protective effects of EEN.

Reintroduction of fiber (MP2-FMT 4) reverted this protective function, indicative for the risk of

relapse in MP2 after EEN cessation (**Fig. 4c**).

Next, we introduced an EEN-like mouse diet one week prior to FMT (MP3-FMT 4) to evaluate

extended dietary effects in gnotobiotic WT and $Il10^{-/-}$ mice (**Fig. 4h**). MP3 had elevated fecal

calprotectin levels of 2828 mg/L (**Fig. 4i**, blue arrow) and ongoing mucosal inflammation with

endoscopic signs of disease activity (**Fig. 4i**, grey arrow), despite achieving clinical remission

under EEN therapy. Accordingly, FMT 1 from MP3 induced severe inflammation in all recipient

$Il10^{-/-}$ mice (**Fig. 4j** histopathology score in $Il10^{-/-}$ = 7.3 ± 0.8 *vs*. WT = 1.3 ± 0.5, p = 0.0022;

Supplementary Fig. 3c H&E). In contrast to MP1 and MP2 (**Fig. 4d, e**), EEN-like medium in

the chemostat model did not change the inflammatory phenotype in IBD-susceptible mice

(MP3-FMT 3, **Fig. 4j** histopathology score in $Il10^{-/-}$ = 6.0 ± 1.3 *vs*. WT = 1.6 ± 1.0, p = 0.0006;

Fig. 4k, H&E, *Tnf* p = 0.0022 for dist. colon and (**Supplementary Fig. 3d**) prox. colon;

Supplementary Fig. 3c). However, introducing EEN-like diet decreased the level of disease

severity after MP3-FMT 4 in most $Il10^{-/-}$ mice (**Fig. 4j** histopathology score in EEN-like-fed

$Il10^{-/-}$ = 3.2 ± 3.1 *vs*. WT = 1.3 ± 0.5, p = n.s.; **Fig. 4k** H&E, *Tnf* p = n.s dist. colon;

Supplementary Fig. 3c, d, *Tnf* p = 0.0022 for prox. colon) and significantly reduced disease

activity compared to the chow-fed group (**Fig. 4j** FMT 3 *vs*. FMT 4**,** histopathology score in

EEN-like-fed $Il10^{-/-}$ = 3.2 ± 3.1, p = 0.0407 (data not shown); **Fig. 4k** H&E, **Supplementary**

Fig. 3c). An additional sample of MP2 after clinical relapse was tested under conditions of the

extended EEN-like feeding (**Fig. 4c**, grey arrow), and contrary to MP3, the MP2 relapse sample

was resistant to EEN induced protection (**Extended Data Fig. 3e-j**). These findings suggest

that sustained EEN-like feeding increased the chance to prevent recurrence, but efficacy of

repeated EEN decreases with a second course.

Individual strain signatures in gnotobiotic $Il10^{-/-}$ mice convey protective function of

patient's microbiota in response to diet

To investigate bacterial strain profiles responsible for the mouse disease phenotypes (**Fig. 4**),
we performed metagenomic analyses of all 54 *Il10*$^{-/-}$ mice from MP1-MP3 (**Fig. 5a-c,** triangles:
red - active disease, green - inactive disease; **Extended Data Fig. 4a**). Out of 105 strains
detected in MP1, 66 were specific to mice with active disease, while only four were specific to
inactive disease (**Fig. 5d,** upper Venn diagram (Vd)). Strains in MP2 mice were skewed
towards being specific to inactive disease (**Fig. 5d,** middle Vd), consistent with lower disease
activity in MP2 and fewer mice with active disease. Strains in MP3 mice were somewhat less
skewed towards being specific to active disease despite a higher number of MP3 mice having
active disease (**Fig. 5d,** lower Vd), perhaps because the same microbiota was transferred but
only the diet was different between FMT 3 and 4.

Motivated by these differences, we next sought to identify species, strains, and metabolites
that distinguished active *vs*. inactive *Il10*$^{-/-}$ mice. Dozens of species showed significant
differential abundance after the transfer experiments of MP1 (40, **Fig. 5e**), MP2 (17, **Fig. 5f**)
and MP3 (12, **Fig. 5g**). *E. clostridioformis, E. bolteae* and *Clostridium innocuum* are the top
significant species in inactive mice of the MP1, MP2 and MP3, respectively. *Akkermansia*
muciniphila, Mediterraneibacter gnavus and *Bacteroides* ssp. were most dominant in mice with
active disease (**Fig. 5e**). SPLS-DA of untargeted metabolomics from mouse gut content
separated active and inactive mice in the respective transfer experiments independent of
dietary exposure (**Fig. 5h-j,** PCA in **Extended Data Fig. 5a-c**). Several bile acids (BA) were
highlighted as differentially abundant, which was confirmed in the targeted measurement
primary taurine conjugated and secondary unconjugated BA (**Extended Data Fig. 4b, c**).
These results clearly demonstrate that despite the model patients having personalized strain
composition (**Fig. 6a,** upper left Vd), disease activity in gnotobiotic mice receiving FMTs was
consistently associated with a number of metabolic and species-level taxonomic differences.
Finally, we investigated the 178 species detected across all transfer experiments, including 22
species shared between MP1-MP3 transfer experiments into *Il10*$^{-/-}$ mice (**Fig. 6a,** upper right
Vd). In total, 31 species were specific to active disease and five to inactive disease (**Fig. 6a,**
lower Vd). Linear discriminant analysis Effect Size (LEfSe) determined 40 species that were
differentially abundant between mice with active *vs*. inactive disease, each with individual
strain repertoires in samples from the three different MPs (**Fig. 6a, b**). SPLS-DA of the
combined untargeted metabolomics dataset confirmed distinct clusters for active and inactive
disease independent of MP1-3 donor samples (**Fig. 6c**, **Extended Data Fig. 5d-e**), suggesting
that individual strain profiles convey protective or aggressive responses in the IBD susceptible
host (**Supplement Fig. 4**). Furthermore, differentially abundant species in humanized mice
showed individual patterns associated with EEN and EEN cessation in the CD patient cohort
(**Fig. 6d**), underscoring the clinical relevance of the differences we observed in our mouse
FMT experiments.

Together, these findings demonstrate that individual species and strain signatures prevent or
cause IBD-like inflammation in gnotobiotic mice. Most importantly, we provide evidence that
EEN therapy creates explicit functional changes of temporally and individually variable
microbiome profiles.

Discussion

We followed 78 pediatric IBD patients longitudinally, focusing on 20 newly diagnosed CD
patients receiving EEN as first-line treatment. Our results corroborate previous observations
that EEN is highly effective at inducing remission. We demonstrate that protective functions of
EEN therapy are mediated through diet-induced changes in patient microbiomes despite
considerable variations in individual microbiota over time. Dietary exposure of individual
patient-derived fecal microbiota in chemostat models and subsequent transfer into IBD-
relevant GF mice strongly indicates a causal role of EEN-mediated changes in the microbiome
independent of host responses. Notably, we demonstrate that a variety of individually different
species and strain signatures convey protective or aggressive disease phenotype in the model
systems, confirming the highly personalized strain-level dynamics in patients.

Longitudinal sampling revealed an integrated network of taxonomic and metabolomic
signatures across pediatric CD patients. In line with previous findings[18], EEN therapy was
associated with the genus *Enterocloster* (Lachnospiraceae; former genus *Lachnoclostridium)*.
In addition, *E. bolteae* and *E. clostridioformis* were the most abundant species in inactive
Il10[-/-] mice. Low levels of *Lachnoclostridium* have been associated with CD[19], supporting a
protective function of *Enterocloster* in response to EEN therapy. Nevertheless, taxonomic shifts
at the cessation of EEN were highly patient-specific. For example, while in the majority of
patients, *E. bolteae* (zOTU5) was at much higher relative abundance during EEN compared to
PostEEN, the dominant strains in many patients changed over this transition, and most strains
were detected in just one subject. This individual diversity and turnover contribute to challenges
in predicting taxonomic responses to dietary changes globally. Antibiotics and pre-existing
dysbiosis are both associated with increased strain engraftment in patients receiving fecal
microbiota transplants[20]. Likewise, the microbiome perturbation caused by EEN - and its
cessation - may encourage strain turnover, with potentially complex consequences for
microbial function after therapy.

Beyond taxonomic alterations, we identified 10 metabolites associated with EEN treatment and
68 metabolites associated with PostEEN samples. Independently, metagenomic analysis
highlighted 577 bacterial gene functions with substantial changes in response to EEN,
suggesting specific metabolic adaptations of the microbiota to host diets. Modulen IBD® is
characterized by easily digestible carbohydrates and high fat content, including medium-chain
triglycerides[9]. Our integrated network analysis highlighted caprylic (C8:0), decanoic (C10:0),

and lauric (C12:0) acids as associated with protective EEN signatures. These medium-chain fatty acids (MCFAs) are part of the EEN formula and mediate anti-bacterial and anti-inflammatory functions[21–23]. Diets high in fat trigger release of bile acids[24], providing a rationale for *C. innocuum* and *Hungatella hathewayi* to be part of protective EEN signatures[25,26]. Concordantly, our untargeted metabolomics analysis identified several BA as differentially abundant, highlighting a potential microbial conversion of primary to secondary bile acids in non-inflamed *Il10*[-/-] mice, potentially promoting wound healing and epithelial regeneration[24]. In a recent study (FARMM), EEN specifically affected amino acid pathways in the microbiome creating a metabolite milieu low in bacteria-derived indoles[27], which was also low abundant in the EEN-like mouse diet. In addition, EEN-related protective effects in *Il10*[-/-] mice are partially mediated by isobutyrate production[28], supporting the hypothesis that microbiota and metabolite changes contribute to the EEN therapeutic efficacy.

In healthy humans, dietary fiber intake supports beneficial functions of the gastrointestinal tract[29]. In animal models, low fiber diets induce adverse microbiota changes associated with impaired intestinal barrier integrity and bacteria-related mucus degradation[30,31], highlighting the fiber paradox in understanding EEN-mediated anti-inflammatory mechanisms in IBD. Dietary fiber consists of complex carbohydrates, which are resistant to digestion and absorption by the host. However, dietary fiber degradation and availability for the host depends on the fermenting potential of host-specific microbial communities, which are modified by intestinal inflammation[29,32,33]. Using the combined gut chemostat-to-mouse transfer approach, we showed that a fiber-free EEN-like medium maintains the anti-inflammatory and remitting phenotype associated with EEN therapy. Concordantly, the protective effect of EEN-conditioned microbiota is reversible upon exposure to fiber-repleted diet and potentially resistant to repetitive EEN as shown before[12]. Recent studies have demonstrated that fiber-free diets prevent and diminish the colonization of identified pathobionts in different CD-like mouse models[34,35], supporting our hypothesis that EEN therapy directly creates protective niches in the gut microbiome. Preserving beneficial microbiome signatures after cessation of EEN may be a new approach to guide mucosal healing and remission in pediatric CD[36]. In our IBD cohort, 40% (8/20) of pediatric CD patients relapsed within the first year after EEN treatment, highlighting the necessity to maintain remitting conditions. Our data clearly demonstrate that EEN therapy mediates protective changes in individually variant microbiome profiles, leading towards personalized patient-to-patient species and strain signatures. These findings support the idea to develop patient-tailored maintenance strategies in pediatric CD involving combinations of personalized nutritional and bacterial interventions.

Funding

Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project number 395357507 (SFB 1371, Microbiome Signatures) and The Leona M. and Harry B. Helmsley Charitable Trust (project numbers 2847 and 2304-05970). TS is supported by the Medical & Clinician Scientist Program (MCSP) of the Faculty of Medicine at LMU Munich. Salary for DHäcker was supported by the National Research Foundation, Prime Minister's Office, Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) programe.

Conflict of interest

DHaller served on the Microbiome Expert Panel from Reckitt Benckiser Health Limited. TS received lecture honoraria from Nutricia and MSD and travel support from Abbvie and Ferring outside the submitted work.

Acknowledgement

We thank the patients and their families for participating in our research.

Author contribution

DHaller and TS are responsible for the conceptual design of the study; DHäcker and DHaller designed the *ex vivo* experiments; KSiebert, HHölz, JHeetmeyer, FDeZen, GLeThi, TS: collected and prepared clinical data and samples, accompanied, followed and characterized patients, analysis of clinical data; HHölz, TS recruited patients; DHäcker, HHeimes, AMetwaly and DHaller performed and interpreted mouse and fermenter experiments; DHäcker performed 16S rRNA gene amplicon and corresponding statistical analysis; CM, QM, KSocas, ML, KK performed metabolomics with statistical analysis; KSiebert, DHäcker, NK, AMetwaly, ML responsible for integration of clinical metadata with 16S and metabolomics as well as sample selection and performance of data integration and network analysis; NK, ML, PJK performed 16S & untargeted metabolomics data integration, untargeted metabolomics data analyses; BS, AMahapatra, KSP performed metagenomic sequencing and analyses; KN provided 16S rRNA gene amplicon and metagenome sequencing and support for analysis; DHäcker, KSiebert, BS, NK, KSP, TS and DHaller evaluated and interpreted data and wrote the manuscript; All authors provided input on the manuscript, critically revised and approved the final version of the manuscript.

358 **ORCID IDs**

Deborah Häcker https://orcid.org/0000-0001-7914-9470

Kolja Siebert https://orcid.org/0009-0005-8083-7074

Byron J Smith https://orcid.org/0000-0002-0182-404X

Nikolai Köhler https://orcid.org/0000-0002-5103-883X

Aritra Mahapatra https://orcid.org/0000-0003-0078-8590

Amira Metwaly https://orcid.org/0000-0001-5740-0230

Hannes Hoelz https://orcid.org/0000-0002-7208-6195

Quirin Manz https://orcid.org/0000-0002-5706-2718

Jeannine Heetmeyer https://orcid.org/0000-0002-0599-9613

Katharina Socas https://orcid.org/0009-0003-8625-4879

Giang Le Thi https://orcid.org/0000-0002-2504-9551

Chen Meng https://orcid.org/0000-0002-5968-6719

Karin Kleigrewe https://orcid.org/0000-0002-7718-0252

Klaus Neuhaus https://orcid.org/0000-0002-6020-2814

Markus List https://orcid.org/0000-0002-0941-4168

Katherine S Pollard https://orcid.org/0000-0002-9870-6196

Tobias Schwerd https://orcid.org/0000-0002-2281-4852

Dirk Haller http://orcid.org/0000-0002-6977-4085

References

1. Torres, J., Mehandru, S., Colombel, J. F. & Peyrin-Biroulet, L. Crohn's disease. *Lancet* **389**, 1741–1755 (2017).

2. Kuenzig, M. E. *et al.* Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. *Gastroenterology* **162**, 1147-1159.e4 (2022).

3. Kaplan, G. G. & Ng, S. C. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* **152**, 313-321.e2 (2017).

4. Liu, Z. *et al.* Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries. *Nat Genet* **55**, 796 (2023).

5. Renz, H. *et al.* Gene-environment interactions in chronic inflammatory disease. *Nature Immunology 2011 12:4* **12**, 273–277 (2011).

6. Van Rheenen, P. F. *et al.* The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. *J Crohns Colitis* **15**, 171–194 (2020).

7. Agrawal, M., Spencer, E. A., Colombel, J. F. & Ungaro, R. C. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. *Gastroenterology* **161**, 47–65 (2021).

8. Bischoff, S. C. *et al.* ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. *Clin Nutr* **42**, 352–379 (2023).

9. Logan, M. *et al.* Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn's disease—new insights into dietary disease triggers. *Aliment Pharmacol Ther* **51**, 935–947 (2020).

10. Logan, M. *et al.* The reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food re-introduction. *Aliment Pharmacol Ther* **50**, 664 (2019).

11. Schwerd, T. *et al.* Exclusive enteral nutrition in active pediatric Crohn disease: Effects on intestinal microbiota and immune regulation. *Journal of Allergy and Clinical Immunology* **138**, 592–596 (2016).

12. Frivolt, K. *et al.* Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: Predictors of efficacy and outcome. *Aliment Pharmacol Ther* **39**, 1398–1407 (2014).

13. Metwaly, A., Reitmeier, S. & Haller, D. Microbiome risk profiles as biomarkers for
inflammatory and metabolic disorders. *Nature Reviews Gastroenterology & Hepatology*
2022 19:6 **19**, 383–397 (2022).

14. Schirmer, M., Garner, A., Vlamakis, H. & Xavier, R. J. Microbial genes and pathways in
inflammatory bowel disease. *Nat Rev Microbiol* **17**, 497 (2019).

15. Lavelle, A. & Sokol, H. Gut microbiota-derived metabolites as key actors in inflammatory
bowel disease. *Nature Reviews Gastroenterology & Hepatology 2020 17:4* **17**, 223–237
(2020).

16. Smith, B. J., Li, X., Shi, Z. J., Abate, A. & Pollard, K. S. Scalable Microbial Strain
Inference in Metagenomic Data Using StrainFacts. *Frontiers in Bioinformatics* **2**, (2022).

17. Metwaly, A. *et al.* Integrated microbiota and metabolite profiles link Crohn's disease to
sulfur metabolism. *Nature Communications 2020 11:1* **11**, 1–15 (2020).

18. Jiang, J., Chen, L., Chen, Y. & Chen, H. Exclusive enteral nutrition remodels the
intestinal flora in patients with active Crohn's disease. *BMC Gastroenterol* **22**, (2022).

19. Vich Vila, A. *et al.* Gut microbiota composition and functional changes in inflammatory
bowel disease and irritable bowel syndrome. *Sci Transl Med* **10**, (2018).

20. Podlesny, D. *et al.* Identification of clinical and ecological determinants of strain
engraftment after fecal microbiota transplantation using metagenomics. *Cell Rep Med*
3, 100711 (2022).

21. Yang, H. T. *et al.* Lauric acid is an inhibitor of Clostridium difficile growth in vitro and
reduces inflammation in a mouse infection model. *Front Microbiol* **8**, 2635 (2018).

22. Kabara, J. J., Swieczkowski, D. M., Conley, A. J. & Truant, J. P. Fatty acids and
derivatives as antimicrobial agents. *Antimicrob Agents Chemother* **2**, 23–28 (1972).

23. Huang, W. C. *et al.* Anti-bacterial and anti-inflammatory properties of capric acid against
Propionibacterium acnes: A comparative study with lauric acid. *J Dermatol Sci* **73**, 232–
240 (2014).

24. Sorrentino, G. *et al.* Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and
Epithelial Regeneration. *Gastroenterology* **159**, 956-968.e8 (2020).

25. Xiao, F. *et al.* Exclusive Enteral Nutrition Exerts Anti-Inflammatory Effects through
Modulating Microbiota, Bile Acid Metabolism, and Immune Activities. *Nutrients* **14**, 4463
(2022).

26. Lv, Y. *et al.* The impact of exclusive enteral nutrition on the gut microbiome and bile acid
metabolism in pediatric Crohn's disease. *Clinical Nutrition* **42**, 116–128 (2023).

27. Tanes, C. *et al.* Role of dietary fiber in the recovery of the human gut microbiome and
its metabolome. *Cell Host Microbe* **29**, 394-407.e5 (2021).

28. Pereira, G. V. *et al.* Unravelling specific diet and gut microbial contributions to
inflammatory bowel disease. *bioRxiv* 2022.04.03.486886 (2022)
doi:10.1101/2022.04.03.486886.

29. Gill, S. K., Rossi, M., Bajka, B. & Whelan, K. Dietary fibre in gastrointestinal health and
disease. *Nature Reviews Gastroenterology & Hepatology 2020 18:2* **18**, 101–116
(2020).

30. Schroeder, B. O. *et al.* Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-
Mediated Colonic Mucus Deterioration. *Cell Host Microbe* **23**, 27-40.e7 (2018).

31. Desai, M. S. *et al.* A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus
Barrier and Enhances Pathogen Susceptibility. *Cell* **167**, 1339-1353.e21 (2016).

32. Haskey, N., Gold, S. L., Faith, J. J. & Raman, M. To Fiber or Not to Fiber: The Swinging
Pendulum of Fiber Supplementation in Patients with Inflammatory Bowel Disease.
Nutrients 2023, Vol. 15, Page 1080 **15**, 1080 (2023).

33. Armstrong, H., Mander, I., Zhang, Z., Armstrong, D. & Wine, E. Not All Fibers Are Born
Equal; Variable Response to Dietary Fiber Subtypes in IBD. *Front Pediatr* **8**, 620189
(2021).

34. Kuffa, P. *et al.* Fiber-deficient diet inhibits colitis through the regulation of the niche and
metabolism of a gut pathobiont. *Cell Host Microbe* (2023)
doi:10.1016/J.CHOM.2023.10.016.

35. Metwaly, A. *et al.* Diet prevents the expansion of segmented filamentous bacteria and
ileo-colonic inflammation in a model of Crohn's disease. *Microbiome* **11**, 66 (2023).

36. Turner, D. *et al.* STRIDE-II: An Update on the Selecting Therapeutic Targets in
Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the
Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in
IBD. *Gastroenterology* **160**, 1570–1583 (2021).

37. Levine, A. *et al.* ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory
Bowel Disease in Children and Adolescents. *J Pediatr Gastroenterol Nutr* **58**, 795–806
(2014).

38.   Turner, D. *et al.* Management of paediatric ulcerative colitis, part 1: Ambulatory Care-An
471   Evidence-based Guideline From European Crohn's and Colitis Organization and
472   European Society of Paediatric Gastroenterology, Hepatology and Nutrition. *J Pediatr*
473   *Gastroenterol Nutr* **67**, 257–291 (2018).

474   39.   Turner, D. *et al.* Management of paediatric ulcerative colitis, part 2: Acute severe colitis
475   - An evidence-based consensus guideline from the european Crohn's and colitis
476   organization and the european society of paediatric gastroenterology, hepatology and
477   nutrition. *J Pediatr Gastroenterol Nutr* **67**, 292–310 (2018).

478   40.   Schult, D. *et al.* Gut bacterial dysbiosis and instability is associated with the onset of
479   complications and mortality in COVID-19. *Gut Microbes* **14**, (2022).

480   41.   Livak, K. J. & Schmittgen, T. D. Analysis of Relative Gene Expression Data Using Real-
481   Time Quantitative PCR and the 2−ΔΔCT Method. *Methods* **25**, 402–408 (2001).

482   42.   Püngel, D. *et al.* Bifidobacterium breve UCC2003 Exopolysaccharide Modulates the
483   Early Life Microbiota by Acting as a Potential Dietary Substrate. *Nutrients* **12**, 948
484   (2020).

485   43.   Macfarlane, G. T., Macfarlane, S. & Gibson, G. R. Validation of a three-stage compound
486   continuous culture system for investigating the effect of retention time on the ecology
487   and metabolism of bacteria in the human colon. *Microb Ecol* **35**, 180–187 (1998).

488   44.   Gibson, G. R. & Wang, X. Enrichment of bifidobacteria from human gut contents by
489   oligofructose using continuous culture. *FEMS Microbiol Lett* **118**, 121–127 (1994).

490   45.   Cinquin, C., Le Blay, G., Fliss, I. & Lacroix, C. Immobilization of infant fecal microbiota
491   and utilization in an in vitro colonic fermentation model. *Microb Ecol* **48**, 128–138 (2004).

492   46.   Poeker, S. A. *et al.* Stepwise Development of an in vitro Continuous Fermentation Model
493   for the Murine Caecal Microbiota. *Front Microbiol* **10**, (2019).

494   47.   Reitmeier, S., Kiessling, S., Neuhaus, K. & Haller, D. Comparing Circadian Rhythmicity
495   in the Human Gut Microbiome. *STAR Protoc* **1**, 100148 (2020).

496   48.   Lagkouvardos, I., Fischer, S., Kumar, N. & Clavel, T. Rhea: A transparent and modular
497   R pipeline for microbial profiling based on 16S rRNA gene amplicons. *PeerJ* **2017**,
498   (2017).

499   49.   Chen, J. *et al.* Associating microbiome composition with environmental covariates using
500   generalized UniFrac distances. *Bioinformatics* **28**, 2106–2113 (2012).

50. Jost, L. Partitioning diversity into independent alpha and beta components. *Ecology* **88**, 2427–2439 (2007).

51. Subramanian, B., Gao, S., Lercher, M. J., Hu, S. & Chen, W. H. Evolview v3: a webserver for visualization, annotation, and management of phylogenetic trees. *Nucleic Acids Res* **47**, W270–W275 (2019).

52. Segata, N. *et al.* Metagenomic biomarker discovery and explanation. *Genome Biol* **12**, R60 (2011).

53. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).

54. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nature Methods 2012 9:4* **9**, 357–359 (2012).

55. Shi, Z. J., Dimitrov, B., Zhao, C., Nayfach, S. & Pollard, K. S. Fast and accurate metagenotyping of the human gut microbiome with GT-Pro. *Nature Biotechnology 2021 40:4* **40**, 507–516 (2021).

56. Almeida, A. *et al.* A unified catalog of 204,938 reference genomes from the human gut microbiome. *Nature Biotechnology 2020 39:1* **39**, 105–114 (2020).

57. Zhao, C., Dimitrov, B., Goldman, M., Nayfach, S. & Pollard, K. S. MIDAS2: Metagenomic Intra-species Diversity Analysis System. *Bioinformatics* **39**, (2023).

58. Reiter, S. *et al.* Development of a Highly Sensitive Ultra-High-Performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry Quantitation Method for Fecal Bile Acids and Application on Crohn's Disease Studies. *J Agric Food Chem* **69**, 5238–5251 (2021).

59. Kessner, D., Chambers, M., Burke, R., Agus, D. & Mallick, P. ProteoWizard: open source software for rapid proteomics tools development. *Bioinformatics* **24**, 2534–2536 (2008).

60. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R. & Siuzdak, G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. *Anal Chem* **78**, 779–787 (2006).

61. Wishart, D. S. *et al.* HMDB 4.0: the human metabolome database for 2018. *Nucleic Acids Res* **46**, D608–D617 (2018).

62. Tsugawa, H. *et al.* MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. *Nature Methods 2015 12:6* **12**, 523–526 (2015).

63.   Duhrkop, K. *et al.* SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite
structure information. *Nature Methods 2019 16:4* **16**, 299–302 (2019).

64.   Singh, A. *et al.* DIABLO: an integrative approach for identifying key molecular drivers
from multi-omics assays. *Bioinformatics* **35**, 3055–3062 (2019).

65.   Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*
(Methodological) **57**, 289–300 (1995).

66.   Blondel, V. D., Guillaume, J. L., Lambiotte, R. & Lefebvre, E. Fast unfolding of
communities in large networks. *Journal of Statistical Mechanics: Theory and Experiment*
2008, P10008 (2008).

67.   Csárdi, G. & Nepusz, T. The igraph software package for complex network research.
InterJournal, Complex Systems **5**, 1–9 (2006).

68.   Hagberg, A. A., Lanlgov -Los, Schult, D. A. & Swart, P. J. S. Exploring Network Structure,
Dynamics, and Function using NetworkX. (2008).

69.   Yoon, S. H. *et al.* Introducing EzBioCloud: A taxonomically united database of 16S rRNA
gene sequences and whole-genome assemblies. *Int J Syst Evol Microbiol* **67**, 1613–
1617 (2017).

Figure 1

Fig. 1: Fecal microbial and metabolic changes in response to EEN.

a Patients of the Pediatric IBD cohort and longitudinal sampling of 804 and 467 stool samples for 16S rRNA amplicon sequencing and metabolome analysis, respectively. Of the 45 CD patients, 37 received Exclusive Enteral Nutrition (EEN). Among these 37 patients, 20 were newly diagnosed and treatment (Tx) naïve. Number of CD samples that were taken under EEN therapy are highlighted in blue. b Beta-diversity analysis of the fecal microbiota in IBD patients. The circular dendrogram shows differences in beta-diversity from the longitudinal microbial profiling based on generalized UniFrac distances between 804 samples of 78 patients of the cohort. Taxonomic composition of fecal samples at the phylum level is shown as color-coded stacked bar blots around the dendrogram. Bars in the first outer ring of the figure show disease phenotypes (CD, UC/IBDU) and EEN treatment in the second outer ring. c Complete clustering of untargeted metabolomic samples with Euclidean distance for 467 longitudinal fecal samples from 59 IBD patients, visualized in a circular tree. d – i Visualizations of beta-diversities concerning samples from the 20 newly diagnosed pCD patients receiving EEN therapy. c Weighted pediatric Crohn's Disease activity index (wPCDAI) over time (EEN shaded blue), remission achieved below 12.5 points (dashed line). pE = PreEEN, EE = EEN, PE = PostEEN. e Alpha-diversity plotted as richness (number of zOTUs) over time as in D. f Beta-diversity analysis of the fecal microbiota samples. The circular dendrogram shows differences in beta-diversities from the longitudinal microbial profiling based on generalized UniFrac distances between the 291 stool samples of the 20 patients. Indicated in color code are the patients and samples collected during EEN. Color code of taxonomic composition at phylum level as in B. g – i Beta-diversity MDS plots: g Active vs. inactive samples (n = 281), h Samples during EEN (at least two weeks on EEN, n = 73) vs. PostEEN (two weeks after end of EEN-induced remission, n = 101), i Start of EEN (StartEEN, n = 34) vs. the very last matching samples under EEN (week 6-9, depending on the individual therapy of patients; EndEEN, n = 36). j – m: Visualization of untargeted metabolome samples from 18 newly diagnosed pediatric CD patients receiving EEN therapy: j Complete clustering with Euclidean distance of longitudinal samples from 18 CD-EEN patients (n = 145), k – m Analyses of untargeted metabolomics with representative PCA plots comparing different groups (color codes as indicated). Axes indicate principal components (PC), with PC1 representing the most variation (%) and PC2 representing the second most variation (%). k Samples during active (n = 99) vs. inactive (n = 46) disease. m Samples during EEN (n = 26) and PostEEN (n = 100; same cut off as in H), m Start (n = 13) vs. end of EEN (n = 13).

Figure 2

Fig. 2: Data integration and identification of features for EEN*:*

a *Correlation network built from selected features based on sPLS-DA-based data integration. Five communities*
were identified (color coded as indicated). Indicated are zOTUs (circles) and metabolites (squares), their
associations to EEN (blue) or PostEEN (orange), and correlation values (lines between features, blue to red). ***b - d***
ROC curves for metabolome and zOTU features, respectively, for Community 1, 2, and 3, grey area ±1 SD. ***e - g***
Most important features (i.e., metabolites and zOTUs) for each community with their feature importance for
PostEEN (<0, orange) and EEN (>0, blue). One dot represents the loading of the respective feature for a single
iteration of the cross-validation procedure (i.e. each iteration is trained on a (stratified) random subset of all data
points). ***h*** *Dotplot of patient-specific expression levels of EEN and PostEEN zOTU signatures (N = 13; all of which*
EEN and PostEEN samples were available) showing individual log fold-changes between expression levels of EEN
and PostEEN samples. The mean of expression was used when more than one sample was available per patient
and condition, i.e. EEN or PostEEN. Blue, higher expression in EEN samples; orange, higher expression levels in
PostEEN samples; white, balanced between conditions; grey, zOTU was not present in the EEN and PostEEN
sample. zOTUs identified with SILVA in the network analyses were re-checked using the 16S-based ID tool of
EzBioCloud[69] using the database update 2023.08.23, reflecting all taxa published and accepted by IJSEM until April
2023.

Figure 3

593   *Fig. 3 – Species and strain turnover during the transition off of EEN:*

594   *a Volcano plots showing COG functions with significant changes in normalized abundance at the transition off of*

595   *EEN (Wilcoxon test at false discovery rate (FDR) < 0.1). Here, 45 COGs were at significantly greater relative depth*

596   *during PostEEN and 532 during EEN. b, c Turnover of taxonomic composition during the transition from EEN to a*

597   *PostEEN diet of both (b) zOTU and (c) strain compositions. The three lines reflect cubic spline regression of Bray-*

598   *Curtis dissimilarities against time, averaged across subjects and offset by an independent intercept for each pair*

599   *type. d Correlation between the relative abundance of zOTU5 and the individual and combined relative abundances*

600   *of the species* Enterocloster bolteae *and* Enterocloster clostridioformis *determined by quantification with shotgun*

601   *metagenomes. The blue diagonal represents a 1:1 relationship in relative abundance. e The distribution of*

602   *correlations between zOTUs and species. In this way, 26 zOTUs matched to one or more metagenomic species*

603   *(**Extended Data Table 2**), including zOTU5 with each of* E. bolteae *and* E. clostridioformis*, had substantially greater*

604   *Pearson correlation than unmatched pairs (p < 10^{-10}, Mann-Whitney U test). f Characterization of species based on*

605   *fold-change in relative abundance between EEN and PostEEN samples and average strain-level turnover, defined*

606   *as the mean Bray-Curtis dissimilarity between within-subject sample pairs. Particularly interesting species were*

607   *identified based on the product of these two statistics, the number of within-subject sample pairs, and the mean*

608   *relative abundance (**Extended Data Table 2**). Points are colored based on this score and the two species matched*

609   *to zOTU5 are circled:* E. bolteae *(red),* E. clostridioformis *(blue). Plots for the 20 highest scoring species are in*

610   ***Supplementary Fig. 2. g, h**. Composition over time of strains within (g)* E. bolteae *(red box) and (h)* E.

611   clostridioformis *(blue box), both abundant in the CD-EEN patients: Both species have noteable strain dynamics*

612   *during and after EEN, but with* E. bolteae *showing higher diversity and turnover. Strain genotypes and fractions*

613   *were estimated from shotgun metagenomic data. Fractions of abundant strains (colored bars) are shown across*

614   *samples from individual subjects (P01, P02…), before EEN ("pE" labels on x-axis), during ("EE") and after ("PE").*

615   *Strain fractions for the species sum to 1; minor strains are summed together and shown in grey.*

Figure 4

Fig. 4: Functional validation of gut microbiota-dependent EEN-efficacy using ex vivo **fermentation and gnotobiotic humanized mice.**

a *Experimental scheme: FMT 1, Patient sample is transferred into GF mice at the age of 8 weeks for 4 weeks. Same patient sample is also transferred (FMT 2) in an* ex vivo *gut chemostat model and treated with medium simulating EEN (EEN-like, devoid of fibers) or a regular diet (fiber-rich, FR). Fermented sample is transferred (post* ex vivo*) into GF mice (age of 8 weeks) for 4 weeks (FMT 3 - EEN-like medium conditioned, FMT 4 - FR medium conditioned).* **b, c** *Transfer of patient sample: patients disease state with wPCDAI and fecal calprotectin levels, therapy response over time with maintenance therapy (MTX, Anti-TNF) and sampling time point.* **b** *Model Patient (MP) 1, sample (red arrow) collected PreEEN in active disease.* **c** *MP2, sample (blue arrow) collected in EEN induced remission.* **d** *Mouse histopathology scoring of colon Swiss roles of FMT 1, 3 and 4 from MP1.* **e** *Mouse histopathology scoring of colon Swiss roles of FMT 1, 3 and 4 from MP2.* **f, g** *Mouse transfer experiments from FMT 3 and 4: Representative (mean of group) H&E stained sections of colonic Swiss roles and corresponding higher magnifications for Il10*$^{-/-}$ *mice (scale bars = 500 µM, HS = histopathology score) respective controls in Extended Data Fig 3) with* Tnf *gene expression levels (fold of control) in distal colon.* **f** *MP1.* **g** *MP2.* **h** *Experimental scheme: Patient sample from MP3 is transferred into GF mice (FMT 1) at the age of 8 weeks, for 4 weeks. Same patient sample is also transferred in an* ex vivo *gut chemostat model and treated with EEN-like medium. Fermented sample is transplanted (post* ex vivo*) into GF mice at the age of 8 weeks, for 4 weeks getting either chow diet (FMT 3) or EEN-like purified diet (EEN-like) one week prior to FMT (FMT 4).* **i** *MP3 sample for transfer (EEN): patients' disease state with wPCDAI and fecal calprotectin, therapy response over time, maintenance therapy (MTX, Anti-TNF) and sampling time point of transferred fecal sample (blue arrow); grey arrow indicates endoscopy performed in the patient PostEEN and the picture taken during endoscopy shows active ileitis.* **j** *Mouse histopathology scoring of colon Swiss roles of FMT 1, 3 and 4 from MP3.* **k** *Mouse transfer experiments from FMT 3 and 4 from MP3: Representative (mean of group) H&E stained sections of colonic Swiss roles and corresponding higher magnifications for Il10*$^{-/-}$ *mice (scale bars = 500 µM, HS = histopathology score) respective controls in Extended Data Fig 3) with* Tnf *gene expression levels (fold of control) in distal colon.* **a, h** *Created with BioRender.com. Data are represented by (**d, e, f, g, j, k**) mean ± SD of six biological replicates. P values were calculated by Mann-Whitney test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001*

Figure 5

Fig. 5: Individual species and strain signatures in recipient Il10$^{-/-}$ mice

a-c *Transfer overview of donor sample (grey) from FMT 1 (black), FMT 3 (EEN-conditioned, blue) and FMT 4 (FR-*

conditioned, brown) into Il10$^{-/-}$ mice. Mouse inflammation end-points are shown (triangles, red = active, green =

inactive). Venn diagrams tally strains detected in inflamed (red), non-inflamed (green) Il10$^{-/-}$ mice or found in both

*conditions (yellow) for **a** MP1 **b** MP2 **c** MP3. **d** Venn diagrams combining strains across FMT1, 3, and 4 for each*

*MP. **e-g** LEfSe (Linear discriminant analysis Effect Size) analysis of differentially abundant bacteria at species level*

based on metagenomic data in the recipient inflamed (active, red) or non-inflamed (inactive, green) Il10$^{-/-}$ mice with

*abundance of strains in each condition. Different strains are labeled with different numbers. **e** MP1. **f** MP2. **g** MP3.*

h-j *Analyses of untargeted metabolomics with representative sPLS-DA plots comparing inflammation in*

Il10$^{-/-}$ mice (inflamed = red; not inflamed = green) from FMT 1, 3 and 4. Axes indicate the sPLS-DA component

*separating the groups. **h** MP1. **i** MP2. **j** MP3. Strain abundance cut-off 20%, species abundance cut-off 10^{-5},*

prevalence ≥ 1.

Figure 6

Fig. 6: Strains associated with active or inactive disease in Il10$^{-/-}$ mice:

a Left Venn diagram shows shared or individual species detected in MP1, MP2 and MP3. Lower Venn diagram

shows shared (yellow) or individual species detected inflamed (red) or not inflamed (green) Il10$^{-/-}$ mice from FMTs

from MP1, MP2 and MP3. Right Venn diagram shows shared or individual strains detected in MP1, MP2 and MP3.

b LEfSe (Linear discriminant analysis Effect Size) analysis of differentially abundant bacteria at species level in all

recipient inflamed (active, red) or non-inflamed (inactive, green) Il10$^{-/-}$ mice from all FMTs performed with abundance

of strains in each MP. Different strains are labeled with different numbers. **c** Visualization of inflamed and non-

inflamed mice on the two identified sPLS-DA components. **d** Abundance of differentially abundant strains from **b** in

all CD-EEN patients (blue = abundant, grey = not detected). Strain abundance cut-off 20%, species abundance cut-

off 10^{-5}, prevalence ≥ 1.

Online Methods

Patient cohort, recruitment and study design

Patients (aged 3-18 years) with suspected or established IBD were recruited to a monocentric pediatric IBD cohort study (ethics approval Ludwig-Maximilians University of Munich, approval No. 17-801 and German Clinical Trials Register Accession No. DRKS00013306, date registration 19.03.2018). All patients and parents/legal guardians provided written informed consent/assent. Patients without confirmed IBD after full diagnostic work-up according to revised Porto criteria were excluded[37]. All other patients were followed prospectively for one year and treated according to current ESPGHAN/ECCO guidelines for CD or ulcerative colitis (UC)/IBD unclassified (IBDU) [6,38,39]. Disease activity, as well as endoscopic, histologic, radiologic and laboratory findings were collected prospectively. Disease activity indices included the Physician Global Assessment (PGA) and the weighted pediatric Crohn's disease activity index (wPCDAI) for CD, as well as the pediatric ulcerative colitis activity index (PUCAI) for UC/IBDU. For EEN-treated CD patients, remission was defined as wPCDAI of <12.5 points and response as reduction in wPCDAI of >17.5 points, but not reaching remission. Relapse was defined as increase of wPCDAI to ≥12.5 points and/or fecal calprotectin of >250 mg/L requiring changes in medical treatment or abdominal surgery or reintroduction of EEN. Patients received detailed instructions for fecal specimen collections and time points, as well as stool collection kits. Each sample was accompanied with a questionnaire on date and time of specimen collection, problems during sampling, Bristol stool scale and recent antibiotic use.

EEN therapy was prescribed for 6-8 weeks, followed by gradual re-introduction of solid food and concomitant start of maintenance treatment. EEN was performed with Modulen® IBD (Nestlé Health Science) or in case of intolerance (e.g. cow's milk protein allergy) with Neocate Junior® (Nutricia, Erlangen, Germany). The amount of prescribed formula was based on the Daily Recommendations Intake (DRI) using the online calculator: https://www.nal.usda.gov/human-nutrition-and-food-safety/dri-calculator. All EEN-treated patients received dietary advice and dietetic support to comply with complete liquid formula feeding.

Fecal specimen collection

Samples were collected at home or in the hospital. Patients provided samples at baseline (before bowel preparation for endoscopy) and every four weeks in (1) 4 mL DNA stabilizer (magiX PBI Microbiome Preservation Buffer, microBIOMix GmbH, Regensburg)[40], (2) 8 mL 20% glycerol in reduced phosphate-buffered saline (PBS, 0.05% L-cysteine) and (3) naïve without stabilizing solution. Patients on EEN collected stool in (1) weekly for the first 12 weeks.

Samples in (1) were shipped at ambient temperature by mail to the study center. Fecal
specimens in (2) and (3) were immediately frozen at home (approx. -18 to -20°C) and brought
in on wet ice packs at the next visit. Upon receipt, samples were aliquoted, barcoded, linked
to clinical data with CentraXX Bio (Kairos GmbH) and stored immediately at -80°C until further
analysis.

Selection of donor samples for transfer experiments into germ-free mice
Stool samples for FMT experiments into germ-free (GF) mice were selected according to the
following criteria: active disease included samples from treatment-naive patients before the
start of EEN (PreEEN), EEN-induced remission (EEN) or reintroduction of a regular diet
(PostEEN).

Animal ethics statement
All animal experiments were conducted at Technical University of Munich and approved by the
Committee on Animal Health Care and Use of the State of Upper Bavaria (TVA ROB-55.2-
2532.Vet_02-19-190) and performed in strict compliance with the EEC recommendations for
the care and use of laboratory animals (European Communities Council Directive of November
24, 1986 (86/609/EEC).

Animals and housing conditions
GF wild-type (WT) and *Il10*-deficient (*Il10*$^{-/-}$) mice on 129Sv/Ev background were bred and kept
at the Core Facility Gnotobiology of the ZIEL Institute for Food & Health, Technical University
of Munich, Freising, Germany. Mice were housed as described elsewhere[17], but using single
gnoto-cage units (Isocage P System, Tecniplast, Italy). Cages are ventilated with HEPA-
filtered air at 22 ± 1°C with a 12-h light/dark cycle. Female and male mice were assigned
randomly to the treatment groups with a ratio of 1:1 and six mice per genotype. Mice received
standard chow (V1124-300; Ssniff, Soest, Germany; autoclaved) or an EEN-like purified diet
(EEN-like, SNIFF S5745-E902, Supplement Fig. 1D) and sterile water *ad libitum*. EEN-like diet
was introduced one week prior to fecal microbial transfer (FMT) to allow for adaptation.
Handling of mice in isocages was performed under biological safety cabinets in sterile
conditions.

Preparing gavage for humanizing germ-free mice
Preparation of FMT with human fecal microbiota was performed according to Metwaly *et al*.
(2020)[17]. For post *ex vivo* FMT, frozen samples in glycerol (20% end concentration) were
thawed on ice. All steps were performed in an anaerobic chamber (90% N_2 and 10% H_2). *Ex*
vivo suspensions (2 mL) were centrifuged at 100×*g* for 3 min at 4°C to pellet debris.
Supernatant was collected and centrifuged at 8000×*g* for 10 min at 4°C to pellet the bacteria.
The bacterial pellet was resuspended in 1.5 mL reduced PBS (0.05% L-cysteine-HCl). The

clear supernatant was transferred into an anaerobic crimped tube, which was transferred to
the gnotobiotic facility. All mice were gavaged on three consecutive days and sacrificed after
four weeks of colonization (12 weeks of age).

Tissue Staining and scoring
Colonic and cecal Swiss-roll tissues were fixed, stained and scored as described before[17]. In
brief, tissue was fixed in 4% formaldehyde/PBS for 48 h at room temperature, subsequently
dehydrated (Leica TP1020), and embedded in paraffin (McCormick; Leica EG1150C).
Formalin-fixed paraffin-embedded (FFPE) tissue sections were stained with hematoxylin and
eosin (H&E) and scored 0 (not inflamed) to 12 (highly inflamed). Inflammation cut off was
defined as a histopathology score greater than three based on scoring in WT mice.

Gene expression
Tissue sections from colon were collected in RNAlater (Sigma Aldrich) for 24 h at 4°C and long-
term at -80 °C until processing. Total RNA from tissue was isolated by using the NucleoSpin
RNA II kit (Macherey-Nagel GmbH) according to manufacturer's instructions. Complementary
DNA was synthetized from 500 ng total RNA by using random hexamers and moloney murine
leukemia virus (M-MLV) reverse transcriptase (RT) Point Mutant Synthesis System (Promega).
Quantification was performed by using the LightCycler 480 Universal Probe Library System
(Roche Primers and probes used were: *Gapdh* (glyceraldehyde 3-phosphate dehydrogenase)
(5'-tccactcatggcaaattcaa-3´; 5' tttgatgttagtggggtctcg-3´; Probe #9) and *Tnf* (Tumor necrosis
factor) (5´-tgcctatgtctcagcctcttc 3´; 5´-gaggccatttgggaacttct-3´; Probe #49). Relative induction
of gene mRNA expression was calculated based the 2-ΔΔCt method [41] using the expression
of *Gapdh* for normalization.

***Ex vivo* gut chemostat model**

The *ex vivo* continuous fermentation was performed in 1.4-L bioreactors (Multifors 2) and
monitored with Eve®software (Infors AG, Basel, Switzerland). Parameters were set as
described before[42]. Briefly, vessels were maintained at 37°C, pH 6.8 with a constant influx of
N_2 to maintain an anaerobic atmosphere. Inoculation material was prepared in an anaerobic
chamber (90% N_2 and 10% H_2). Approximately 2.5 g of frozen fecal samples was suspended
in reduced PBS supplemented with 0.03 g/mL L-cysteine-HCl, filtered (70 µm Cell Strainer,
FisherScientific) and evenly distributed between two vessels, which led to about 1.0×10^8 to
8.16×10^8 CFU/vessel. Two consecutive batch fermentations (24 h in 400 mL, another 24 h
with fresh 400 mL medium added) allowed fecal microbial communities to establish.
Continuous fermentation included complete medium exchange every 36 h (retention time) with
a working volume of 400 mL. After 10 days of continuous fermentation, where stable
community formation was achieved, samples for transfer into GF mice were collected and

medium was switched afterwards. After 1.5 days of complete medium exchange from medium 1 to medium 2, samples for transfer into mice were collected on day 9 of continuous fermentation in the second medium. Medium composition was either fiber-rich (FR) or EEN-like, mimicking patient conditions at sampling (PreEEN and PostEEN, respectively; **Extended Data Fig.1a-e**).

FR medium was prepared according to Macfarlane *et al*. (1998)[43], but supplemented with additional vitamins (pantothenate 10 mg/L, nicotinamide 5 mg/L, thiamine 4 mg/L, biotin 2 mg/L, vitamin B12 0.5 mg/L, menadione 1 mg/L, and p-aminobenzoic acid 5 mg/L) as described in Gibson and Wang[44]. EEN-like medium was based on the Macfarlane medium, but with modifications simulating colonic-luminal content during an EEN diet. To determine the carbohydrate:protein ratio of digested Modulen IBD® in the colon, similar calculations as described previously were conducted[45,46]. Since Modulen IBD® lacks fibers, these ingredients present in the FR medium (i.e., pectin from citrus, guar gum, xylan from oat spelt, inulin from *Dahlia* tubers, and arabinogalactan from larch wood) were replaced by soluble rice starch and simple sugars. A total carbohydrate concentration of 13 g/L was chosen in alignment with Cinquin *et al.* (2004)[45]. As the formulation of Modulen IBD® is not publicly available, we decided to include some Modulen IBD® not to miss crucial nutrients in our model-colon medium. Towards this end, 10% v/w of Modulen IBD® was added to the EEN-like medium. Finally, the carbohydrate:protein ratio was 75:25 in the model medium. To further mimic Modulen IBD®, casein was used as main protein source with the exclusion of tryptone and peptone (**Supplement Fig. 1a-c**).

Samples were aseptically collected daily at the same daytime and stored at -80°C until further analyses. Samples for transfer into the GF mice were collected and mixed with glycerol (20% end concentration) and stored at -80°C until gavage preparation. In order to diminish potential vessel effects in the technical duplicates of each fermenter colonization, samples from both vessels were mixed 50:50 for gavage.

High-throughput 16S-ribosomal RNA (rRNA) gene amplicon sequencing analysis
Total DNA from human stool, colonic mouse content and the continuous *ex vivo* fermentation was isolated using bead beating and sequenced for 16S rRNA gene amplicons as described[47]. Downstream analysis was performed in R v4.2.1 using Rhea (https://lagkouvardos.github.io/Rhea/)[48]. zOTU tables were normalized to 10.000 reads, beta-diversity was computed using generalized UniFrac distances[49]. Alpha-diversity was assessed on the basis of taxa richness and Shannon effective number of zOTUs[50]. Trees were visualized and annotated using EvolView (http://www.evolgenius.info/evolview/)[51]. Differential analyses of bacteria in different groups was done using LDA Effect Size (LEfSe)[52]. zOTUs were re-

checked using the 16S-based ID tool of EzBioCloud[69] using the database update 2023.08.23,
reflecting all taxa published and accepted by IJSEM until April 2023.

Shotgun Metagenomic Sequencing and Analysis
Metagenomic sequencing was performed for 96 human stool samples and 66 samples from
transfer experiments (54 mouse, 12 *ex vivo*) using the genomic DNA already isolated for 16S
rRNA gene amplicon sequencing. DNA was randomly sheared into short fragments. The
obtained fragments were end repaired, A-tailed, and further ligated with Illumina adapters. The
fragments with adapters were size-selected, PCR amplified, and purified. The library was
checked with Qubit and real-time PCR for quantification and BioAnalyzer for size distribution
detection as required by Illumina (TruSeq® DNA Library Prep Kit). Quantified libraries were
pooled and sequenced on a NovaSeq platform (Illumina) in PE150 mode. Raw data were
aimed at 15 Gb per demultiplexed sample. From raw shotgun metagenomic sequencing data,
adapter sequences were removed using Trimmomatic v0.39[53] without considering any
mismatch and parameters LEADING:3, TRAILING:3, and SLIDINGWINDOW:4:15. We
removed human reads by mapping against human reference genome hg38 by using Bowtie2
v2.4.5 [54] with the default parameters. Cleaned fastq data files were used in the following steps.

Strain tracking and strain gene content analyses were performed based on the StrainPGC
workflow [@Smith2023, https://github.com/bsmith89/StrainPGC]. Briefly, preprocessed
metagenomes were metagenotyped using GT-Pro v1.0.1[55]. Across all samples, 369 species -
as defined in the Unified Human Gut Genome (UHGG)[56] - were robustly detected and only
these were included in downstream pangenome profiling. Single nucleotide polymorphism
(SNP) profiles were filtered, subsampled, and strain relative abundances were estimated with
StrainFacts v0.4.0[16]. Within individual species, estimated strain fractions add up to 100%. By
contrast, other analyses considered the overall strain composition: the relative abundance of
each strain across all species.

Gene profiling was performed against a subset of the MIDASDB-UHGG pangenome database
v.15[57] dereplicated at a 99% ANI threshold performed and mapping reads using Bowtie2
v2.4.5[54]. Species abundances were estimated based on the average depth of core genes.
Global functional gene family profiling was performed by aggregating gene depths into Clusters
of Orthologous Genes (COGs) across all species and then normalizing based on 25 ubiquitous,
single-copy genes to estimate "gene copies per genome".

Metabolomics

Sample preparation / Metabolites extraction
Sample preparation of mouse colon content. Approximately 20 mg of mouse colon content
was weighed in a 2 mL bead beater tube (FastPrep-Tubes, Matrix D, MP Biomedicals Germany

GmbH, Eschwege, Germany). Next, 1 mL of methanol-based dehydrocholic acid extraction
solvent (c = 1.3 µmol/L) was added as an internal standard for work-up losses. The samples
were extracted with a bead beater FastPep-24TM 5G (MP Biomedicals Germany GmbH,
Eschwege, Germany) supplied with a CoolPrepTM (MP Biomedicals Germany, cooled with dry
ice) 3-times each for 20 s of beating at a speed of 6 m/s and followed by a break of 30 s each.
Sample preparation of fermenter or human samples. Either 200 mg of the fermenter
samples or 100 mg of human fecal samples was weighed in a 15 mL bead beater tube
(FastPrep-Tubes, Matrix D, MP Biomedicals Germany GmbH, Eschwege, Germany). Next,
5 mL of methanol-based dehydrocholic acid extraction solvent (c = 1.3 µmol/L) was added as
an internal standard for work-up losses. The samples were extracted with the same FastPrep
protocol described above.
Targeted bile acid measurement. A standard of 20 µL of isotopically labeled bile acids (ca. 7
µM each) were added to 100 µL of sample extract. Targeted bile acid measurement was
performed using a QTRAP 5500 triple quadrupole mass spectrometer (Sciex, Darmstadt,
Germany) coupled to an ExionLC AD (Sciex, Darmstadt, Germany) ultrahigh performance
liquid chromatography system. A multiple reaction monitoring (MRM) method was used for the
detection and quantification of the bile acids according to Reiter et. al.[58] Data acquisition and
instrumental control were performed with Analyst v1.7 software (Sciex, Darmstadt, Germany).
Untargeted mass spectrometric measurement. The untargeted analysis was performed
using a Nexera UHPLC system (Shimadzu, Duisburg, Germany) coupled to a Q-TOF mass
spectrometer (TripleTOF 6600, AB Sciex, Darmstadt, Germany). Separation of the fecal
samples was performed either using a UPLC BEH Amide 2.1 × 100 mm, 1.7 µm analytic
column (Waters, Eschborn, Germany) with a 400 µL/min flow rate or with a Kinetex XB18 2.1
x 100 mm, 1.7 µm (Phenomenex, Aschaffenburg, Germany) with a 300 µL/min flow rate. For
the HILIC-separation the settings were as follows: The mobile phase was 5 mM ammonium
acetate in water (eluent A) and 5 mM ammonium acetate in acetonitrile/water (95/5, v/v) (eluent
B). The gradient profile was 100% B from 0 to 1.5 min, 60% B at 8 min and 20% B at 10 min to
11.5 min and 100% B at 12 to 15 min. For the reversed-phase separation, eluent A was 0.1%
formic acid and eluent B was 0.1% formic acid in acetonitrile. The gradient profile started with
0.2% B which was held for 0.5 min. Afterwards, the concentration of eluent B was increased
to 100% until 10 min which was held for 3.25 min. Subsequently, the column was equilibrated
at starting conditions. A volume of 5 µL per sample was injected. The autosampler was cooled
to 10 °C and the column oven heated to 40 °C. Every tenth run, a quality control (QC) sample,
which was pooled from all samples, was injected. The samples were measured in a
randomized order and in the Information Dependent Acquisition (IDA) mode. MS settings in
the positive mode were as follows: Gas 1 55, Gas 2 65, Curtain gas 35, Temperature 500 °C,
Ion Spray Voltage 5500, declustering potential 80. The mass range of the TOF MS and MS/MS

scans were 50–2000 m/z and the collision energy was ramped from 15–55 V. MS settings in

the negative mode were as follows: Gas 1 55, Gas 2 65, Cur 35, Temperature 500 °C, Ion

Spray Voltage -4500, declustering potential -80. The mass range of the TOF MS and MS/MS

scans were 50–2000 m/z and the collision energy was ramped from -15–55 V.

Data processing

The "msconvert" from ProteoWizard[59] was used to convert raw files to mzXML (de-noised by

centroid peaks). The bioconductor/R package xcms[60] was used for data processing and

feature identification. More specifically, the matchedFilter algorithm was used to identify peaks

(full width at half-maximum set to 7.5 s). Then the peaks were grouped into features using the

"peak density" method[60]. The area under the peak was integrated to represent the abundance

of features. The retention time was adjusted based on the peak groups presented in most

samples. To annotate features with names of metabolites, the exact mass and MS2

fragmentation pattern of the measured features were compared to the records in HMBD[61] and

the public MS/MS spectra in MSDIAL[62], referred to as MS1 and MS2 annotation, respectively.

Missing values were imputed with half of the limit of detection (LOD) methods, i.e., for every

feature, the missing values were replaced with half of the minimal measured value of that

feature in all measurements. To confirm a MS2 spectra is well annotated, we manually

reviewed our MS2 fragmentation pattern and compared it with records in the public database,

previously measured reference standards and SIRIUS[63] to evaluate the correctness of the

annotation. Significances of well-annotated metabolic features were computed with analysis

of variance (ANOVA) per donor or Wilcoxon signed-rank tests and FDR-corrected using the

Benjamin-Hochberg method for three donors. Subsequent hierarchical clustering using only

differentially abundant metabolites (q < 0.05) was conducted using complete linkage based on

Euclidean distances. Calculations, as well as heatmaps, were computed in R v4.2.1. For each

principal component analysis (PCA), we included negative and positive features from RP and

HILIC with at least 50% non-missing values per condition (inflamed/non-inflamed). The

remaining missing values were imputed as described above. The prcomp function from R

v4.3.2 computed the principal components after centering and scaling each feature to zero

mean and unit variance. Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) was

performed on centered and scaled features using the mixOmics bioconductor/R package

v6.26.0[64]. Mean balanced error rate, was used to select the number of components and

features in M-fold cross-validation where M corresponds to the minimum number of samples

per condition. **Extended Data Fig. 5e** shows raw values for features with the highest Variable

Importance in the Projection (VIP), i.e., features contributing the most to explaining the

conditions.

Data integration of 16s rRNA amplicon data with metabolomics and metagenomics

We matched 60 samples from 15 patients of the 16S-rRNA gene sequencing to 60 samples of

the untargeted metabolomics analysis according to patient ID and same time points. The aim

was to discriminate features between 23 EEN samples (clinical phenotype mild and remission)

and 37 PostEEN samples (>2 weeks after EEN, clinical remission). For the integrated selection

of metabolome and microbiota features, sPLS-DA (mixOmics v6.20) was used[64]. For feature

selection concerning metabolomics, only annotated metabolites were considered. As

described above, input metabolites were mean-centered and scaled to unit variance. zOTUs

(zero-radius operational taxonomic units) were centered log-ratio transformed. To estimate the

degree of overfitting, the model was trained on 70% of the data, with a k-fold cross-validation

for feature selection during training. The remaining 30% of the data were used to evaluate the

generalization power. The model performance was measured with an Area Under the Receiver

Operating Characteristic (ROC-AUC). This procedure was done once with the actual labels

and 200-times with randomized labels, to obtain an empirical p-value for the model prediction

on the validation data. Subsequently, Spearman's rank correlation coefficients between all

selected metabolites and zOTUs were computed and their respective p-values were corrected

with the Benjamini-Hochberg procedure[65]. All coefficients with an FDR >0.05 were set to 0.

Using all non-zero correlations, a network was generated and the Louvain method for

community detection[66] was applied to extract highly connected subgraphs from the correlation

network. For each community, a sPLS-DA model was trained with the same train-test and

randomization scheme explained previously for feature selection. Feature importance was

plotted using the loadings in each iteration and determining their association to either EEN or

PostEEN. Analyses were run in R v4.2.1 and python v3.8.11. For network analysis the igraph

v1.3.4[67] and networkx v3.1[68] packages were used.

Profiles of 16S rRNA amplicon relative abundance were further integrated with metagenomic

species profiles in order to identify those which represent the same, underlying taxa. This was

done by calculating the Pearson correlation coefficient between each zOTU relative

abundance and species relative abundances estimated from the metagenomic workflow. Each

correlation was then weighted by the mean relative abundance of that zOTU and species,

respectively, producing a matrix of matching scores for each comparison. Based on this score,

we ranked zOTUs for each species and species for each zOTU. We selected as putative

matches all zOTU-species pairs that were either reciprocal best hits or a combination of one

best hit and one second-best hit. In this way, we accounted for the possibility of multiple zOTUs

representing a species or multiple species being represented by a zOTU.

Statistical analysis

Further statistical analyses and plots were generated using GraphPad Prism v8.0 (GraphPad,

La Jolla, CA) using Mann-Whitney test, ANOVA followed by pairwise comparison testing

(Tukey, Bonferroni correction), by Kruskal-Wallis test followed by Dunn`s multiple comparisons.

Data is presented as mean ± SD. P-values below 0.05 were considered significant ($p < 0.05$,

*; $p < 0.01$, **; $p < 0.001$, ***; and $p < 0.0001$, ****).

Taxonomic turnover in both zOTU and strain compositions were calculated based on the Bray-

Curtis dissimilarity. Pairs where one sample was collected during EEN and the other during

PostEEN were classified as "transition". All within-subject pairwise comparisons were

computed and fit using cubic spline regression of the time between sample collections, with a

regression term for each subject, as well as for each pair class: EEN, transition, or PostEEN.

The null hypothesis of no difference between pair classes was tested by permutation: 999

random permutations of samples within subjects. Changes in mean, normalized, COG depths

during EEN and PostEEN time points were tested using the Wilcoxon signed-rank test across

subjects. False discovery rates were calculated using the Benjamini-Hochberg procedure.

Mean fold change for each COG was calculated as the ratio between these two estimates.

Data availability

The data that support the findings of this study will be available on reasonable request from

the corresponding author [TS]. The data are not publicly available due to the pediatric age of

the research participants. Mouse untargeted metabolomics data is available at Massive

(https://massive.ucsd.edu) under the number MSV000094047. All other data will be available

at the time of publication.

Code availability

Mutliomic data integration of 16S rRNA and metabolomics code is available at

https://doi.org/10.5281/zenodo.10808412. All code necessary to reproduce the metagenomic

data analysis will be made publicly available at the time of publication.